Search
Surrozen Inc
SRZNAdd to Watchlist
24.920USD
-0.600-2.35%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
243.59MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.35%
5 Days
-1.19%
1 Month
+2.21%
6 Months
+15.64%
Year to Date
+10.27%
1 Year
+198.09%
Key Figures
25.830Open
26.825High
99.79KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.02%Turnover Ratio
25.520Prev. Close
24.710Low
1.81MTurnover
LossP/E Static
-1.30P/B
0.00%Div Yield TTM
-290.88%ROA
35.00052wk High
0.54Volume Ratio
-63.56MNet Profit
9.78MShares
-36.5766EPS TTM
0.52Beta
-62.80%ROE
7.60052wk Low
8.29%Amplitude
100.00%Gross Margin
243.59MMarket Cap
0.96Reward/Risk
4.89%Risk Rate
TradingKey Stock Score of Surrozen Inc
Currency: USD Updated: 2026-07-02Key Insights
Surrozen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 42.67.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Surrozen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Surrozen Inc Highlights
StrengthsRisks
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.48M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.48M.
Fairly Valued
The company’s latest PE is -0.68, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 10.96M shares, increasing 15.48% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.33.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
42.667
Target Price
+67.19%
Upside Space
Surrozen Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Surrozen Inc Info
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
Ticker SymbolSRZN
CompanySurrozen Inc
CEOParker (Craig C)
Websitehttps://www.surrozen.com
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Surrozen Inc (SRZN)?
The current price of Surrozen Inc (SRZN) is 24.92.
What is the symbol of Surrozen Inc?
The ticker symbol of Surrozen Inc is SRZN.
What is the 52-week high of Surrozen Inc?
The 52-week high of Surrozen Inc is 35.00.
What is the 52-week low of Surrozen Inc?
The 52-week low of Surrozen Inc is 7.60.
What is the market capitalization of Surrozen Inc?
The market capitalization of Surrozen Inc is 243.59M.
Is Surrozen Inc (SRZN) currently rated as Buy, Hold, or Sell?
According to analysts, Surrozen Inc (SRZN) has an overall rating of Buy, with a price target of 42.67.
What is the Earnings Per Share (EPS TTM) of Surrozen Inc (SRZN)?
The Earnings Per Share (EPS TTM) of Surrozen Inc (SRZN) is -32.37.